}

Tolterodine

Urologicals

Drug Overview

Tolterodine, marketed under the brand name Detrol, is an oral antimuscarinic agent used in the management of overactive bladder.

It is indicated to reduce symptoms of urinary urgency, frequency, and urge incontinence associated with overactive bladder.

The drug works by competitively inhibiting M2 and M3 muscarinic receptors in the detrusor muscle of the bladder, thereby decreasing involuntary contractions and improving bladder capacity.

Relevant Genes and Their Roles

The primary gene affecting tolterodine metabolism is CYP2D6, which encodes a liver enzyme in the cytochrome P450 family responsible for converting tolterodine into its active and inactive metabolites. Metabolism refers to the body's process of breaking down and eliminating a drug.

Variations in CYP2D6 activity—caused by inherited genetic differences—can alter how quickly tolterodine is processed. Individuals with different CYP2D6 variants may metabolize the drug too quickly, too slowly, or at a normal rate, impacting both efficacy and safety.

Impact of Genetics on Drug Response

Genetic variations in CYP2D6 classify individuals as ultrarapid, normal, intermediate, or poor metabolizers, which can influence tolterodine plasma levels, therapeutic efficacy, and risk of adverse effects such as QT prolongation.

Expected Clinical Effects of Genetic Variation

Ultrarapid Metabolizer

  • Effect on drug levels: Normal to slightly lower drug levels due to faster metabolism
  • Clinical consequence: Typical therapeutic response; no dose adjustment recommended
  • Side effects: Similar to general population; no increased severity or frequency reported

Normal Metabolizer

  • Effect on drug levels: Expected drug levels with standard metabolism
  • Clinical consequence: Standard efficacy and safety profile
  • Side effects: Typical anticholinergic effects (dry mouth, constipation); mild and common

Intermediate Metabolizer

  • Effect on drug levels: Slightly elevated drug levels due to reduced metabolism
  • Clinical consequence: Generally adequate response; monitor for side effects
  • Side effects: Possible mild increase in anticholinergic effects (dry mouth, constipation)

Poor Metabolizer

  • Effect on drug levels: Higher drug levels due to slow metabolism
  • Clinical consequence: Increased risk of adverse reactions, particularly QT prolongation
  • Side effects: Higher likelihood of anticholinergic side effects and cardiac effects; moderate severity

Indeterminate/Not Available

  • Effect on drug levels: Unknown
  • Clinical consequence: No specific guidance; follow standard dosing with clinical monitoring
  • Side effects: Unknown; monitor patient as usual

Dosing Guidelines

The following dosing guidelines are based on the FDA's Table of Pharmacogenetic Associations.

CYP2D6 Dosing Guideline

Phenotype Clinical Consequence Guideline Recommendation
Ultrarapid Metabolizer No FDA guidance for this phenotype Use standard starting dose
Normal Metabolizer No FDA guidance for this phenotype Use standard starting dose
Intermediate Metabolizer No FDA guidance for this phenotype Use standard starting dose
Poor Metabolizer Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation) Use standard dose with ECG monitoring; monitor for adverse reactions
Indeterminate / Not available Unknown impact Initiate standard starting dose

Alternative Treatment Options

The FDA guideline does not specify alternative treatments based on CYP2D6 genotype. In practice, other antimuscarinic agents such as oxybutynin or darifenacin may be considered as examples, but individual treatment decisions should be made by a qualified healthcare professional.

Sources and References

Disclaimer: This document is for informational purposes only and is not a substitute for medical advice. Clinical decisions should be made by a qualified healthcare professional.

Interested in learning more about how your genetics may affect your response to medication? Get started with Gene2Rx today.

I'm Interested